Literature DB >> 17213012

Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study.

Alexandra Ward1, Khajak Ishak, Irina Proskorovsky, Jaime Caro.   

Abstract

OBJECTIVE: The objective of this analysis was to describe the patterns of compliance with atypical antipsychotics among patients with schizophrenia in actual practice in 2 Canadian provinces and to examine the relation between degrees of compliance and the risks of hospitalization, suicide, and death.
METHODS: Adults with a diagnosis of schizophrenia who filled at least 1 prescription for risperidone, olanzapine, or quetiapine were identified in the Quebec public prescription drug insurance plan database (from July 1, 2001, to December 31, 2004) and the Saskatchewan Health database (from January 1, 1999, to December 31, 2003). Compliance was assessed based on the medication possession ratio, which was estimated as the proportion of days for which medication was available over each month of follow-up (> or = 80% = good compliance; 50%-79% = moderate compliance; < 50% = poor compliance). The association between the early and long-term effects of compliance and the risks of hospitalization, suicide, and death were examined using Cox regression, with adjustment for baseline age, sex, and use of antidepressants, sedatives, and lithium (Quebec only).
RESULTS: respective 41,754 and 3291 patients were identified from the Quebec and Saskatchewan databases. Approximately half of the patients in each cohort were male and were aged < 45 years. Many patients had good compliance over the full follow-up period (Quebec, 61%; Saskatchewan, 45%); however, poor compliance was seen in 23% of patients from Quebec and 34% of those from Saskatchewan. Compared with poor compliance, the long-term effect of good compliance was associated with a significantly decreased risk of all-cause hospitalization (Quebec: adjusted hazard ratio [HR] = 0.60; 95% CI, 0.57-0.64; Saskatchewan: adjusted HR = 0.81; 95% CI, 0.69-0.95) and psychosis-related hospitalization (Quebec: adjusted HR = 0.37; 95% Cl, 0.34-0.40; Saskatchewan: adjusted HR = 0.45; 95% CI, 0.32-0.64). The Quebec data also indicated a significant association between good versus poor compliance and a decreased risk of death (adjusted HR = 0.58; 95% CI, 0.51-0.66) and suicide (adjusted HR = 0.68; 95% CI, 0.55-0.84) that was not observed in Saskatchewan.
CONCLUSION: In this retrospective analysis of patients with schizophrenia in Quebec and Saskatchewan, good compliance with atypical antipsychotic medications was associated with substantial reductions in the risk for all-cause and psychosis-related hospitalizations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17213012     DOI: 10.1016/j.clinthera.2006.11.002

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  20 in total

1.  How reimbursement databases can be used to support drug utilisation studies: example using the main French national health insurance system database.

Authors:  Philippe Latry; Mathieu Molimard; Bernard Bégaud; Karin Martin-Latry
Journal:  Eur J Clin Pharmacol       Date:  2010-04-29       Impact factor: 2.953

2.  Existing and novel biological therapeutics in suicide prevention.

Authors:  Joshua J Griffiths; Carlos A Zarate; J J Rasimas
Journal:  Am J Prev Med       Date:  2014-09       Impact factor: 5.043

Review 3.  Managing suicide risk in patients with schizophrenia.

Authors:  John Kasckow; Kandi Felmet; Sidney Zisook
Journal:  CNS Drugs       Date:  2011-02       Impact factor: 5.749

4.  Suicidal behavior in the older patient with schizophrenia.

Authors:  John Kasckow; Lori Montross; Laurie Prunty; Lauren Fox; Sidney Zisook
Journal:  Aging health       Date:  2011-06

Review 5.  A plea for a more epidemiological and patient-oriented pharmacovigilance.

Authors:  Veronica Scurti; Marilena Romero; Gianni Tognoni
Journal:  Eur J Clin Pharmacol       Date:  2011-07-20       Impact factor: 2.953

6.  Major self-mutilation in the first episode of psychosis.

Authors:  Matthew Large; Nick Babidge; Doug Andrews; Philip Storey; Olav Nielssen
Journal:  Schizophr Bull       Date:  2008-05-20       Impact factor: 9.306

7.  Suicidality in middle aged and older patients with schizophrenia and depressive symptoms: relationship to functioning and Quality of Life.

Authors:  J Kasckow; L Montross; S Golshan; S Mohamed; T Patterson; E Sollanzano; S Zisook
Journal:  Int J Geriatr Psychiatry       Date:  2007-12       Impact factor: 3.485

8.  All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: a cohort study.

Authors:  Chin-Kuo Chang; Richard D Hayes; Matthew Broadbent; Andrea C Fernandes; William Lee; Matthew Hotopf; Robert Stewart
Journal:  BMC Psychiatry       Date:  2010-09-30       Impact factor: 3.630

9.  Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study.

Authors:  Ariel Berger; John Edelsberg; Kafi N Sanders; Jose Ma J Alvir; Marko A Mychaskiw; Gerry Oster
Journal:  BMC Psychiatry       Date:  2012-08-02       Impact factor: 3.630

10.  Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review.

Authors:  José M Olivares; Jan Sermon; Michiel Hemels; Andreas Schreiner
Journal:  Ann Gen Psychiatry       Date:  2013-10-23       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.